ADAR1 Capital Management LLC Decreases Stake in Solid Biosciences Inc. (NASDAQ:SLDB)

ADAR1 Capital Management LLC decreased its holdings in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 87.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 148,903 shares of the company's stock after selling 996,689 shares during the period. ADAR1 Capital Management LLC owned about 0.37% of Solid Biosciences worth $596,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of SLDB. JPMorgan Chase & Co. grew its position in shares of Solid Biosciences by 9,393.8% during the fourth quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company's stock worth $3,824,000 after buying an additional 945,863 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in Solid Biosciences by 292.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 443,010 shares of the company's stock worth $3,088,000 after acquiring an additional 330,234 shares in the last quarter. Trexquant Investment LP raised its holdings in shares of Solid Biosciences by 256.9% in the 4th quarter. Trexquant Investment LP now owns 194,281 shares of the company's stock valued at $777,000 after purchasing an additional 139,851 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Solid Biosciences by 183.6% during the 3rd quarter. Wellington Management Group LLP now owns 119,804 shares of the company's stock worth $835,000 after purchasing an additional 77,564 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Solid Biosciences by 412.1% during the 3rd quarter. Barclays PLC now owns 62,856 shares of the company's stock worth $439,000 after purchasing an additional 50,582 shares during the last quarter. Hedge funds and other institutional investors own 81.46% of the company's stock.

Remove Ads

Solid Biosciences Trading Up 1.1 %

Shares of Solid Biosciences stock traded up $0.03 on Friday, reaching $2.70. 566,026 shares of the stock were exchanged, compared to its average volume of 881,789. The firm has a market capitalization of $209.23 million, a PE ratio of -0.89 and a beta of 2.07. Solid Biosciences Inc. has a 1-year low of $2.48 and a 1-year high of $10.99. The business has a fifty day moving average price of $4.38 and a two-hundred day moving average price of $4.81.

Analyst Ratings Changes

A number of research firms have weighed in on SLDB. Truist Financial began coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a "buy" rating and a $16.00 price target on the stock. JPMorgan Chase & Co. decreased their target price on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating for the company in a research note on Thursday, March 13th. Chardan Capital reiterated a "buy" rating and issued a $16.00 price target on shares of Solid Biosciences in a research note on Friday, March 7th. HC Wainwright increased their price objective on Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a report on Monday, March 10th. Finally, Wedbush assumed coverage on shares of Solid Biosciences in a report on Friday, December 13th. They issued an "outperform" rating and a $16.00 target price on the stock. Eight analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, Solid Biosciences currently has a consensus rating of "Buy" and an average target price of $15.67.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.